DexCom, Inc. (DXCM) to Post Q4 2018 Earnings of $0.12 Per Share, Piper Jaffray Companies Forecasts

Share on StockTwits

DexCom, Inc. (NASDAQ:DXCM) – Research analysts at Piper Jaffray Companies upped their Q4 2018 earnings per share (EPS) estimates for DexCom in a research note issued to investors on Tuesday, January 8th. Piper Jaffray Companies analyst J. Mckim now expects that the medical device company will earn $0.12 per share for the quarter, up from their prior forecast of $0.09. Piper Jaffray Companies currently has a “Overweight” rating and a $165.00 target price on the stock. Piper Jaffray Companies also issued estimates for DexCom’s Q4 2019 earnings at $0.24 EPS, FY2019 earnings at $0.17 EPS and FY2020 earnings at $0.63 EPS.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, November 6th. The medical device company reported $0.17 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.29. DexCom had a net margin of 4.72% and a negative return on equity of 2.89%. The firm had revenue of $266.70 million during the quarter, compared to analysts’ expectations of $242.72 million. The firm’s revenue for the quarter was up 44.5% on a year-over-year basis.

Other equities analysts have also recently issued reports about the stock. UBS Group lifted their price objective on shares of DexCom from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday. Oppenheimer set a $150.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research report on Thursday, December 6th. Northland Securities raised shares of DexCom from an “under perform” rating to a “market perform” rating in a research report on Wednesday, September 12th. Goldman Sachs Group raised shares of DexCom from a “sell” rating to a “neutral” rating and set a $125.00 price objective for the company in a research report on Friday, October 19th. Finally, Morgan Stanley lifted their price objective on shares of DexCom from $130.00 to $150.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 11th. Seven equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $137.06.

DXCM stock opened at $138.75 on Thursday. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.71 and a quick ratio of 4.43. DexCom has a one year low of $52.92 and a one year high of $152.14. The firm has a market cap of $10.33 billion, a price-to-earnings ratio of -239.22 and a beta of 0.63.

Institutional investors and hedge funds have recently bought and sold shares of the company. Waddell & Reed Financial Inc. raised its stake in DexCom by 164.8% in the second quarter. Waddell & Reed Financial Inc. now owns 569,331 shares of the medical device company’s stock valued at $54,075,000 after purchasing an additional 354,331 shares in the last quarter. Swiss National Bank raised its stake in DexCom by 1.0% in the third quarter. Swiss National Bank now owns 153,600 shares of the medical device company’s stock valued at $21,971,000 after purchasing an additional 1,500 shares in the last quarter. BlackRock Inc. raised its stake in DexCom by 5.9% in the second quarter. BlackRock Inc. now owns 4,116,421 shares of the medical device company’s stock valued at $390,978,000 after purchasing an additional 228,933 shares in the last quarter. Macquarie Group Ltd. raised its stake in DexCom by 14.4% in the second quarter. Macquarie Group Ltd. now owns 236,341 shares of the medical device company’s stock valued at $22,448,000 after purchasing an additional 29,825 shares in the last quarter. Finally, Northern Trust Corp raised its stake in DexCom by 4.3% in the second quarter. Northern Trust Corp now owns 451,647 shares of the medical device company’s stock valued at $42,896,000 after purchasing an additional 18,631 shares in the last quarter. 98.79% of the stock is owned by institutional investors.

In other news, CEO Kevin R. Sayer sold 11,162 shares of DexCom stock in a transaction on Monday, December 10th. The stock was sold at an average price of $121.67, for a total transaction of $1,358,080.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steven R. Altman sold 2,500 shares of DexCom stock in a transaction on Wednesday, January 2nd. The stock was sold at an average price of $117.04, for a total value of $292,600.00. Following the sale, the director now directly owns 3,449 shares of the company’s stock, valued at approximately $403,670.96. The disclosure for this sale can be found here. Insiders have sold 62,995 shares of company stock valued at $8,434,505 in the last three months. Insiders own 1.80% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: Stochastic Momentum Index (SMI)

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Analysts Set Workday Inc  Price Target at $158.74
Analysts Set Workday Inc Price Target at $158.74
Lam Research Co.  Given Consensus Recommendation of “Buy” by Analysts
Lam Research Co. Given Consensus Recommendation of “Buy” by Analysts
Teck Resources  Shares Up 5.1%
Teck Resources Shares Up 5.1%
Five9  Trading Down 5.2%
Five9 Trading Down 5.2%
Albemarle  Releases FY 2019 Earnings Guidance
Albemarle Releases FY 2019 Earnings Guidance
Espers  Price Reaches $0.0001 on Major Exchanges
Espers Price Reaches $0.0001 on Major Exchanges


© 2006-2019 Ticker Report